PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.410 enrolled

Overview

The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

410

Conditions

Lymphoma

Interventions

PEG-rhG-CSFDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with age ≥ 18 years * diagnosis of lymphoma(Hodgkin's lymphoma and non-Hodgkin's lymphoma) patients * Karnofsky Performance Status Z70 * life expectancy of at least 8 months * normal white blood cell count and platelet count * Written informed consent are acquired Exclusion Criteria: * uncontrolled infection * pregnancy * Have accepted any other anti-tumor drug within 4 weeks before anticipated the study * Other situations that investigators consider as contra-indication for this study

Outcomes

Primary Outcomes

The occurrence rate of adverse event

Time frame: up to 30 days after the patient study completion

The severity of adverse event

Time frame: up to 30 days after the patient study completion

Secondary Outcomes

the occurrence rate of grade III/ IV neutropenia during chemotherapy cycles

Time frame: through the study completion,an average of 5 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.